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ABSTRACT
CONTEXT AND OBJECTIVE: Hereditary angioedema (HAE) with C1 inhibitor deficiency manifests as re-
current episodes of edema involving the skin, upper respiratory tract and gastrointestinal tract. It can be 
lethal due to asphyxia. The aim here was to evaluate the response to therapy for these attacks using icati-
bant, an inhibitor of the bradykinin receptor, which was recently introduced into Brazil. 
DESIGN AND SETTING: Prospective experimental single-cohort study on the efficacy and safety of icati-
bant for HAE patients. 
METHODS: Patients with a confirmed HAE diagnosis were enrolled according to symptoms and regardless 
of the time since onset of the attack. Icatibant was administered in accordance with the protocol that has 
been approved in Brazil. Symptom severity was assessed continuously and adverse events were monitored. 
RESULTS: 24 attacks in 20 HAE patients were treated (female/male 19:1; 19-55 years; median 29 years of 
age). The symptoms were: subcutaneous edema (22/24); abdominal pain (15/24) and upper airway ob-
struction (10/24). The time taken until onset of relief was: 5-10 minutes (5/24; 20.8%); 10-20 (5/24; 20.8%); 
20-30 (8/24; 33.4%); 30-60 (5/24; 20.8%); and 2 hours (1/24; 4.3%). The time taken for complete resolution 
of symptoms ranged from 4.3 to 33.4 hours. Adverse effects were only reported at injection sites. Mild 
to moderate erythema and/or feelings of burning were reported by 15/24 patients, itching by 3 and no 
adverse effects in 6.  
CONCLUSION: HAE type I patients who received icatibant responded promptly; most achieved improved 
symptom severity within 30 minutes. Local adverse events occurred in 75% of the patients. 
RESUMO
CONTEXTO E OBJETIVO: O angioedema hereditário (AEH) com deficiência de inibidor de C1 manifesta-se 
por episódios recorrentes de edema envolvendo pele, trato respiratório superior e gastrointestinal. Pode 
ser letal por asfixia. O objetivo foi avaliar a resposta à terapia dos ataques com icatibanto, inibidor do re-
ceptor de bradicinina, recentemente introduzido no Brasil.
TIPO DE ESTUDO E LOCAL: Estudo experimental prospectivo de coorte, sem grupo controle, da eficácia 
e segurança do icatibanto em paciente com AEH. 
MÉTODOS: Pacientes com diagnóstico confirmado de AEH foram incluídos de acordo com os sintomas, 
independentemente do tempo de início do ataque. Icatibanto foi administrado segundo protocolo aprovado 
no Brasil. A gravidade do sintoma foi estabelecida continuamente e os eventos adversos foram monitorados. 
RESULTADOS: 24 ataques em 20 pacientes com AEH foram tratados (19 F:1 M; 19-55 anos; mediana 29 anos). 
Os sintomas foram: edema subcutâneo (22/24), dor abdominal (15/24) e obstrução de vias aéreas superio-
res (10/24). O tempo para o início do alívio foi: 5-10 minutos, 5/24 (20,8%); 10-20, 5/24 (20,8%); 20-30, 8/24 
(33,4%); 30-60, 5/24 (20,8%) e 2 horas, 1/24 (4,3%). O tempo para a resolução completa variou de 4,3-33,4 ho-
ras. Somente efeitos adversos nos locais das injeções foram relatados. Eritema leve a moderado e/ou sensação 
de ardor foram relatados por 15/24 pacientes, prurido em 3, e 6 não tiveram efeitos adversos.
CONCLUSÃO: Pacientes com AEH tipo I receberam icatibanto com pronta resposta; a maioria teve melho-
ra na gravidade dos sintomas em 30 minutos. Eventos adversos locais ocorreram em 75% dos pacientes.
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INTRODUCTION
Hereditary angioedema (HAE) with C1 inhibitor (C1-INH) 
deficiency is a rare disease that manifests as recurrent episodes 
of subcutaneous edema, most commonly involving the skin, 
upper respiratory tract, oropharynx and gastrointestinal tract. 
Two  forms of HAE have been described: type I HAE with low 
C1-INH antigenic protein and functional activity (85% of the 
cases); and type II HAE with normal or elevated protein but low 
C1-INH function (15% of the cases).1,2 The disease is disabling 
and can be lethal.1,3,4 No official data exists concerning complica-
tions and deaths due to asphyxia among Brazilian HAE patients, 
but these outcomes have been registered by the Brazilian 
Association of HAE Patients (ABRANGHE) over recent years 
(personal communication).
The pathogenesis of edema attacks due to HAE remains elu-
sive. In several reports, bradykinin was found to mediate swell-
ing. Its plasma levels increased during attacks and mice that were 
deficient in both C1-INH and the bradykinin receptor 2 (BR-2) 
gene showed diminished vascular permeability,5-7 thus confirm-
ing the previous evidence. Considering the importance of brady-
kinin binding and activation of BR-2 in angioedema formation in 
HAE patients, it would be possible for acute attacks to be treated 
with the BR-2 antagonist, icatibant.  
Effective management of HAE targets either prevention or 
treatment of attacks.1 Drugs for both approaches have been avail-
able since the late 1970s, but not uniformly registered.2 In Brazil, 
until icatibant was approved recently, fresh frozen plasma was the 
only available therapy for acute HAE attacks. 
OBJECTIVE
The aim of this study was to describe the clinical response of HAE 
patients to therapy for HAE attacks using icatibant, an inhibitor 
of the bradykinin receptor, and the possible side effects. This was 
the first report on the use of this new drug in a real-life setting.
METHODS
We conducted a prospective experimental single-cohort study on 
20 patients who were treated using icatibant. In order to be eligi-
ble for treatment in accordance with the Brazilian approval, adult 
patients needed to have a documented diagnosis of hereditary 
angioedema (including a low C4 level, a normal C1q level and 
a low antigenic or functional C1 inhibitor level) and to have a 
well-documented history at outpatient clinics, as stipulated in the 
Brazilian guidelines.1 The exclusion criteria for treatment were 
other differential diagnoses of HAE (drugs such as hormones 
and angiotensin converser enzyme (ACE) inhibitors), preg-
nancy and age greater than 65 years. Subjects were not required 
to change any of their regular medications, including andro-
gens or antifibrinolytic drugs. Icatibant was administered during 
an attack of moderate or severe intensity, involving the abdo-
men, face or external genitalia, with symptoms of upper airway 
obstruction such as a change in voice tone and difficulty in swal-
lowing, regardless of the time that had elapsed since the onset of 
symptoms. The severity of the attacks was established in accor-
dance with Giavina-Bianchi et al.1 and Bowen et al.2 One syringe 
(30 mg) of icatibant was slowly administered subcutaneously in 
the abdominal wall. Brazilian legislation also stipulates that a sec-
ond injection of the same drug could be administered if neces-
sary, six hours after the first administration.
Prior to icatibant administration, all participants were 
informed about its effects and potential adverse reactions and 
gave their consent to treatment. Self-administration is not 
allowed, according to Brazilian legislation; therefore, all injec-
tions were administered under medical supervision, as estab-
lished by the Brazilian Health Surveillance Agency (Agência 
Nacional de Vigilância Sanitária, ANVISA), with access to medi-
cal emergency facilities. 
The physicians and the patients were asked to describe the 
symptoms at each site affected (extremities, throat, abdomen, 
face and external genitalia). Symptom severity was assessed con-
tinuously until the subject reported achieving relief. The patients 
were allowed to leave the hospital facilities after improvement, 
but were subsequently contacted to confirm that complete reso-
lution of symptoms had occurred. Safety was evaluated by assess-
ing adverse events, changes in physical findings and vital signs 
before and after the injection.
RESULTS
From August 2011 to February 2012, 24 attacks were treated 
using icatibant, in 20 HAE type 1 patients (19 females and one 
male). One patient was treated four times and another, twice, in 
different attacks. The median age at the initial appearance of HAE 
symptoms was 5 years old (range 1-28 years), with median age 
at diagnosis of 23 years (range 5-54 years). The youngest patient 
treated with icatibant was 19 years old and the oldest, 55 years old 
(median 29 years) (Figure 1). 
The following involvement was observed during the attacks: 
subcutaneous edema (22/24); gastrointestinal pain (16/24); 
upper airway obstruction (12/24), reported as changes in voice 
tone and swallowing difficulty; and laryngeal edema (2/24) 
(Figure 2). Facial edema was observed in 16/24 and in nine cases 
was also associated with abdominal pain. Gastrointestinal pain 
alone was present in 1/24 patients only. In 18 patients, the HAE 
attack was classified as severe and in six as moderate. At the time 
of the treatment for the HAE attack, fifteen patients were taking 
androgen prophylaxis (4/15 using oxandrolone and 11/15 using 
danazol), one patient was being treated with antifibrinolytics and 
eight patients were not undergoing any specific therapy.
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Administration of icatibant was started at an average of 
6.3 hours (median = 6 hours; range 2-12 hours) after the onset 
of symptoms. The estimated time taken for relief to begin after 
the injection was: 5-10 minutes (5/24; 20.8%); 10-20 (5/24; 
20.8%); 20-30 (8/24; 33.4%); 30-60 (5/24; 20.8%); and two 
hours (1/24; 4.3%) (Figure 3). The upper airway obstruction 
improved first, followed by the abdominal pain, whereas the 
skin swelling took a longer time to resolve. The time taken to 
achieve complete resolution of symptoms was variable, from 
4.3 to 33.4 hours. None of the patients required more than one 
injection for the same episode; however, two patients presented 
recurrence within 24 hours but with no medical intervention, 
and spontaneous regression occurred. Mild to moderate ery-
thema and/or feelings of burning were reported in the cases 
of 15/24 applications; itching was described after injections in 
3  cases; and 6  treatments had no adverse effect. The patient 
who was treated for four different attacks showed a good clini-
cal response in each instance, and the time from treatment to 
the resolution of symptoms remained constant.
DISCUSSION
In this study, we reported on treatment using icatibant dur-
ing 24 episodes of acute swellings in HAE type I patients in a 
real-life setting in Brazil. All the patients showed good clini-
cal responses to this treatment and most of them reported clin-
ical relief even before any change was observed in cutaneous 
swelling. The initial onset of relief was earlier for upper air-
way obstruction symptoms. Subcutaneous edema was the clin-
ical manifestation that persisted the longest. Most of the 
patients showed an improvement in respiratory and gastroin-
testinal symptoms within 30 minutes following the injection. 
Importantly, total regression of the complaints occurred within 
24 hours (median), in comparison with attacks in which there 
was no specific drug therapy, which lasted three to five days, as 
previously reported.8,9 
Evaluation of icatibant was performed in three controlled tri-
als: FAST-1, FAST-2 and FAST-3. In the FAST-1 trial, statistical 
significance between the drug and placebo regarding the time 
taken to achieve symptom relief was not found, although the 
patients receiving icatibant reported the first endpoint improve-
ment after 2.5 hours and those with the placebo, after 4.6 hours. 
The analysis parameters used in this trial and the time taken for 
the treatment to be introduced probably influenced the results.8,10 
In the second study, the efficacy of icatibant was compared with 
tranexamic acid and a significant reduction in symptoms was 
observed (2.0 hours versus 12.0 hours). FAST-3, which was a ran-
domized placebo-controlled study, demonstrated that icatibant 
was effective in treating HAE attacks in adults (88 subjects; 43 
with icatibant and 45 with placebo).10
Figure 1. Age at the time of first symptoms, age at diagnosis and 
icatibant application among hereditary angioedema patients. 
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Figure 3. Time taken to achieve initial relief from symptoms during 
hereditary angioedema attacks. 
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Figure 2. Clinical symptoms presented by hereditary angioedema 
patients before icatibant application.
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In our series of patients, the upper airway obstruction symp-
toms were the first to resolve. Greve at al. found the same results 
after reporting on administration of icatibant in 141 attacks in a 
single patient.11 During the FAST studies, most of the laryngeal 
attacks were treated as an open-label phase and the median time 
taken to achieve relief was longer than one hour.8,10 The discrep-
ancy between the findings from those studies and our results may 
be due to the different analysis parameters used in those stud-
ies. The quick response may have been associated with anatomi-
cal issues in the upper airways, in which even a small amount 
of edema can lead to significant clinical repercussions. Also, this 
observation points to the importance of mediation of this symp-
tom through bradykinin binding to B2 receptors, which is a lead-
ing cause of death in HAE patients. 
Icatibant is approved in Brazil for use under medical super-
vision only, i.e. patients are not allowed to inject themselves. 
This resulted in a delay in the therapy with a median elapsed 
time of 6 hours until application, and a maximum of 12 hours. 
However, this did not influence the efficacy of the therapy, since 
our patients who received therapy more than 10 hours after the 
attack started achieved improvement within the same length of 
time as shown by those who had early access to medical assis-
tance, as has previously been reported.12 Development of home 
treatment strategies for patients with HAE is an important step 
towards improving the management of this debilitating condi-
tion, which would lead to a better response and, consequently, 
better quality of life.12,13 Approval for self-administration is under 
analysis by the Brazilian authorities.
The attack was classified as severe in approximately 60% of 
the patients studied (14/24), and suggestive clinical manifesta-
tions associated with laryngeal edema were the indication for ica-
tibant use in 50% of the situations in our report. The patients 
reported that voice changes and facial edema were the sensations 
that preceded airway obstruction. Although no official classifi-
cation of severity is available, the Brazilian guidelines was used 
for therapy indication.1 Therefore, the severity of the disease may 
explain some of the delays in achieving complete improvement 
that were seen in some individuals in this subgroup of patients. 
However, patients could choose to have even mild attacks of HAE 
treated, if the therapy was available. In addition, combination of 
preventive and on-demand therapy with reduction of the andro-
gen dose and treatment of breakthrough attacks using C1 inhibi-
tor or icatibant has been proposed.14,15 Such observations are lim-
ited by the type of study developed, with no control group.
Two patients who received icatibant more than once did 
not  observe any reduction in the efficacy of the therapy and 
did  not present any increase in adverse events. Greve et al. 
reported that icatibant was used 141 times in one patient without 
any loss of efficacy.11 There were no adverse events in one third of 
our cases and the complaints reported consisted of local burning, 
hyperemia and mild itching. These symptoms were self-limited 
and related to local release of histamine induced by subcutane-
ous injection of icatibant, a development that may be attenuated 
by H1-antihistamines.16
Sixty percent (12/20) of the patients who received icatibant 
were undergoing prophylactic treatment with androgens. In fact, 
the approved therapy for HAE within the public healthcare sys-
tem in Brazil only includes danazol. It has been estimated that 
about 25% and 50% of the HAE patients in Switzerland and 
Austria, respectively, receive long-term therapy with androgens, 
with variable indications.15 Long-term prophylaxis with attenu-
ated androgens is effective in many patients, but side effects such 
as virilization in females, weight gain and other factors result in 
restrictions on their use. It is possible that restricted access to 
therapy probably leads physicians to introduce prolonged use of 
drugs as well as higher androgen doses in HAE patients.
Brazil was the only South American country with access 
to icatibant at the time of reporting this experience. The health 
authorities in Colombia and Argentina have approved icatibant, 
but the drug is not available yet.17 Regarding diagnosis and ther-
apy of HAE in Latin America, we are at the forefront of a pro-
cess that is just beginning,18 except in Argentina, where the first 
reports were published almost 30 years ago and plasma-derived 
C1 inhibitor is available.17 Icatibant was launched three years ago 
in Brazil and the use of this drug is not financially supported by 
the government, although some health insurance companies 
reimburse its use on demand. 
Most of the patients (65%) reported their first symptoms 
when they were five years old; only four of them presented after 
adolescence. The median age for diagnosis was 23  years, thus 
suggesting that there is a delay in identifying HAE patients. 
One  patient was 55 years old by the time that the disease 
was recognized, but its symptoms first presented when she was 
15 years old; her case is a testament to how restricted knowledge 
about HAE is. If we consider the fact that there is almost no reg-
istration of cases in other Latin American countries, it becomes 
obvious that many opportunities to treat HAE patients have been 
lost. Gastrointestinal complaints were reported by 62.5% of our 
patients and were not associated with facial edema in 21% of the 
cases treated in our experience.
Marqués et al. reported that one potential future use for ica-
tibant would be for short-term prophylactic HAE treatment, and 
they reported on its use for a patient with previous severe attacks 
during some procedures.19 The patients who may benefit from 
switching to on-demand therapy, or from combining preventive 
and on-demand therapy, include women, children and adoles-
cents, as well as patients with various risk factors for androgens 
such as organ toxicity, cardiovascular disease or possible drug 
interactions.20 Use of icatibant has been restricted for patients 
under 18 years of age and for patients with cardiac diseases.21 
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Medication cost is a major concern for both patients and 
physicians. The US Hereditary Angioedema Association has esti-
mated that hospital stays and emergency department visits dur-
ing acute attacks comprise 68% of the cost of a severe attack.22 
As understanding of HAE physiopathology and management 
improves, decisions regarding continuous or on-demand therapy 
should become easier, and studies evaluating pharmacoeconom-
ics will certainly help. 
CONCLUSIONS
The HAE type I patients who received icatibant responded 
promptly; most of them achieved improved symptom sever-
ity within 30 minutes. Mild local adverse events were reported 
in 75% of the patients. The introduction of this new drug has 
opened up new perspectives for HAE patients regarding thera-
pies for attacks.
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